Access to early-phase clinical trials for children with relapsed and refractory neuroblastoma: A multicentre international study.
Marta CortesFernando CarcellerAlba Rubio-San-SimónSucheta J VaidyaFrancisco J Bautista SirventLucas MorenoPublished in: Pediatric blood & cancer (2022)
Although two thirds of children with refractory/relapsed neuroblastoma were enrolled in early-phase trials, recruitment rates can still be improved. The main cause for not participating on trials was not fulfilling eligibility criteria prior to consent, mainly due to performance status and short life expectancy. This study highlights the hurdles to access to innovative therapies for children with relapsed/refractory neuroblastomas, and identifies key areas of development to improve recruitment to early-phase trials.